Group 1 - The Hong Kong Stock Connect innovative drug sector showed strong performance, with companies like InnoCare Pharma-B rising over 9% and 3SBio increasing by more than 8% [1] - The Hong Kong Stock Connect Innovative Drug ETF (520880) has fully invested in innovative drug R&D companies, surging over 3.6% with trading volume exceeding 200 million yuan [1][3] - The ETF has seen a significant inflow of funds, accumulating 130 million yuan over the past four days [1] Group 2 - The European Society for Medical Oncology (ESMO) annual meeting is scheduled from October 17 to October 21, 2025, in Berlin, with several innovative drug companies like CanSino Biologics and Kelun-Bio presenting clinical data on new technologies [3] - Analysts expect that the ESMO meeting, along with potential business development catalysts in Q4, may lead to a second wave of market activity for innovative drugs [3] - The Hong Kong Stock Connect Innovative Drug ETF (520880) is designed to track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which excludes CXO companies and focuses solely on innovative drug R&D [4] Group 3 - As of the end of September, the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has increased by 108.14% year-to-date, outperforming other innovative drug indices [4][5] - The ETF has a total fund size of 1.806 billion yuan and an average daily trading volume of 493 million yuan since its inception, making it the largest and most liquid ETF in its category [5]
第二波行情启动？高弹性港股通创新药ETF（520880）冲高3.6%！映恩生物-B、三生制药、康方生物集体飙升